INVESTORS

In June 2010, Calistoga announced closing of a today Series C financing for $40 million. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners. The funds will be used to advance Calistoga Pharmaceuticals' drug development pipeline of isoform-selective PI3K inhibitors.

Alta Partners

Alta Partners is a San Francisco-based venture capital firm focused on life sciences investing. Founded in 1996, the firm currently manages $2 billion in committed capital through eight venture fund programs. Alta invests in life sciences companies across the development continuum, from company formation to later-stage opportunities, and has funded more than 110 companies in the sector to date.

Amgen Ventures

Amgen Ventures, formed in 2004, is a corporate venture capital fund designed to provide emerging biotechnology companies with resources to develop pioneering discoveries focused on human therapeutics. Amgen Ventures reflects Amgen's commitment to helping patients. The fund can offer early stage companies access to Amge's extensive capabilities while providing Amgen with insight into external research innovations that may pave the way for future collaborations.

Frazier Healthcare Ventures

Founded in 1991 and with more than $1.2 billion of capital under management, Frazier Healthcare is one of the nation's leading providers of venture and growth equity capital to emerging healthcare companies. Having invested in more than 113 emerging healthcare companies to date, Frazier Healthcare is well known for its depth of experience and the technical expertise of its investment team. This experience encompasses product development and launch, clinical trial implementation and design, industry operating experience, academic research and clinical practice. Partnering with Frazier Healthcare provides access to capital and an unparalleled breadth of relevant healthcare industry experience.

Latterell Venture Partners

Latterell Venture Partners (LVP) is a San Francisco based venture capital firm specializing in creating and investing in early stage healthcare companies. The LVP partners have more than 100 years of combined experience building new biopharmaceutical and medical device companies, and have played a significant role at a large number of successful biotechnology companies. More information regarding LVP is available at www.LVPcapital.com.

Three Arch Partners

Three Arch Partners was formed in 1993 to provide young companies with access to relevant clinical and business resources, as well as capital. Three Arch Partners has helped create, build, and fund more than 100 healthcare companies. The investment focus is on opportunities in medical devices and healthcare services, as well as biotechnology and information technology. The partnership manages over $1 billion in capital.